Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06667934

Clinical Trial of Zuoqing SAN in Treating Ulcerative Colitis

Status
Not Yet Recruiting
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The exact efficacy of Zuoqing SAN enema in the treatment of Ulcerative colitis (UC) has been clinically verified. In this study, Zuoqing SAN was used to treat UC patients with large intestine damp-heat syndrome, and the traditional chinese medicine (TCM) syndrome type was large intestine damp-heat syndrome. The changes of symptoms and signs of patients before and after treatment were observed and compared, and the clinical efficacy of Zuoqing SAN in the treatment of UC large intestine damp-heat syndrome was evaluated by combining the changes of patients' symptoms, related blood indicators, improved Mayo total score, overall syndrome efficacy, clinical comprehensive efficacy and other aspects. By replicating the rat UC model, the effects of Zuoqing SAN on general survival state, colonic gross appearance and histopathological changes, related inflammatory factors, peroxisome proliferator-activated receptor γ (PPAR-γ) /nuclear factor kappa-B(NF-κB) /signal transducerand activator of transcription 1 (STAT1) pathway, macrophage M1, M2 phenotype and microangiogenesis were observed in UC rats. Thus, the specific mechanism of Zuoqing SAN in the treatment of UC was revealed. In this study, the therapeutic effect of Zuoqing Powder on UC was investigated through clinical and animal experiments, and the specific mechanism of action was studied.

Conditions

Interventions

TypeNameDescription
DRUGZuoqing powder was dissolved in 100ml normal saline, retained enema, once a nightZuoqing powder was dissolved in 100ml normal saline, retained enema, once a night
DRUGMethalazine suppository was given rectally once a dayMethalazine suppository was given rectally once a day

Timeline

Start date
2024-10-30
Primary completion
2025-05-01
Completion
2025-05-01
First posted
2024-10-31
Last updated
2024-10-31

Source: ClinicalTrials.gov record NCT06667934. Inclusion in this directory is not an endorsement.